TILT Biotherapeutics to evaluate TILT-123, avelumab combo in solid tumours

This article was originally published here

TILT-123 has been engineered to selectively replicate only in cancer cells that produce the TNFa and IL-2 immunostimulatory cytokines locally at the tumour as shown in various in

The post TILT Biotherapeutics to evaluate TILT-123, avelumab combo in solid tumours appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply